5 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Primary: To characterize the safety and tolerability of PDR001 in combination with LCL161, everolimus, HDM201, QBM076 or panobinostat and to identify recommended doses and schedules for future studies.Secondary: To characterize changes in the immune…
Objectives: To test the hypothesis that the thyroid gland of offspring of long-lived siblings is more resistant to stimulation with TSH compared to the thyroid gland of their partners, offspring and partners will receive a low dose of recombinant…